ReviewClinical reviews in allergy & immunology2023
Inflammaging and Frailty in Immune-Mediated Rheumatic Diseases: How to Address and Score the Issue.
Review in Clinical reviews in allergy & immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications.Cardiovascular diabetology · 2025Pooled it
- Immunological Insights into the Causal Link Between Arthritis, Osteoarthritis, and Frailty: An Integrated Analytical Study.International journal of medical sciences · 2025Pooled it
- Is sarcopenia a real concern in ankylosing spondylitis? A systematic literature review.European geriatric medicine · 2024Pooled it
- Frailty Assessment in Polymyalgia Rheumatica: Comparative Performance and Determinants of Clinical-Research Frailty Assessment (CRAF) and Kihon Checklist (KCL) Scores.Journal of clinical medicine · 2026Article
- Systemic Lupus International Collaborating Clinics Frailty Index predicts mortality in systemic lupus erythematosus patients: data from the Almenara Lupus Cohort.Lupus science & medicine · 2026Article
- Association of Frailty and Delirium with Hospitalization Outcomes Among Older Adults With Rheumatic Diseases.ACR open rheumatology · 2026Article
- Frailty Transition and Risk of New-Onset Arthritis Among Adults Aged 45 Years and Older: A Longitudinal Analysis of CHARLS.Healthcare (Basel, Switzerland) · 2026Article
- Health-Related Quality of Life in Older Adults with Rheumatoid Arthritis: A Sex-Specific Case-Control Analysis of Physical and Mental Health Domains.Journal of clinical medicine · 2026Article
- Nutritional Risk in Older Adults with Rheumatoid Arthritis: Sex-Specific Patterns and Clinical Implications of the Prognostic Nutritional Index.Nutrients · 2026Observational
- Insights Into Late-Onset Rheumatoid Arthritis (LORA): Characteristics (Clinical and Imaging), Comorbidities, and Therapeutic Targets.Geriatrics & gerontology international · 2026Review
- Hormonal and Cytokine Imbalances Promote a Proinflammatory Profile in Institutionalized Elderly.Brain sciences · 2025Article
- Diet, Lifestyle Factors, and Quality of Life in Patients with Rheumatic Diseases: A Cross-Sectional Study.Nutrients · 2025Article
- Prevalence of Frailty and Associated Factors in a US-Wide Cohort of Rheumatic Diseases.ACR open rheumatology · 2025Article
- Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia.International journal of molecular sciences · 2025Review
- Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles.Frontiers in pharmacology · 2025Article
- Frailty and associated risk factors in patients with Sjögren's disease: a cross-sectional study.Frontiers in immunology · 2025Article
- Explainable machine learning model for pre-frailty risk assessment in community-dwelling older adults.Health care science · 2024Article
- Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus.RMD open · 2024Article
- [Treatment response and complications of older patients with ANCA(antineutrophil cytoplasmatic antibody)-associated vasculitis].Zeitschrift fur Gerontologie und Geriatrie · 2023Article
- [Frequency and severity of sarcopenia in patients with inflammatory and noninflammatory musculoskeletal diseases : Results of a monocentric study in a tertiary care center].Zeitschrift fur Rheumatologie · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is a new concept in rheumatology that can help identify people more likely to have less favorable outcomes. Sarcopenia and inflammaging can be regarded as the biological foundations of physical frailty. Frailty is becoming more widely accepted as an indicator of ageing and is linked to an increased risk of negative outcomes such as falls, injuries, and mortality. Frailty identifies a group of older adults that seem poorer and more fragile than their age-matched counterparts, despite sharing similar comorbidities, demography, sex, and age. Several studies suggest that inflammation affects immune-mediated pathways, multimorbidity, and frailty by inhibiting growth factors, increasing catabolism, and by disrupting homeostatic signaling. Frailty is more common in the community-dwelling population as people get older, ranging from 7 to 10% in those over 65 years up to 40% in those who are octogenarians. Different parameters have been validated to identify frailty. These primarily relate to two conceptual models: Fried's physical frailty phenotype and Rockwood's cumulative deficit method. Immune-mediated rheumatic diseases (IMRDs), such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, and vasculitis, are leading causes of frailty in developing countries. The aim of this review was to quantitatively synthesize published literature on the prevalence of frailty in IMRDs and to summarize current evidence on the relevance and applicability of the most widely used frailty screening tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.